January’s CE was the kickoff to NYCSHP’s 2016’s education series! President, Dr. Yi Guo, welcomed back members and gave an update on NYCSHP’s upcoming events. President Guo extended the welcome by introducing the NYCSHP board of directors and committee chairs and thanking the evening’s sponsor.
President Guo, introduced the evening’s first presenter, a physician involved in the phase III clinical trial that granted Aptiom’s (eslicarbazepine) FDA indication for partial-onset seizures. This discussion highlighted the long term complications of seizure disorders and the role anti-epileptics have in the treatment of epilepsy.
Aptiom has been studied in patients with relapse or refractory seizure disorders and has shown efficacy in this population. Patient adherence is essential to preventing further complications to ensure adequate levels in the body. Although measuring serum levels is most common, the importance is high penetration into the CNS, which Aptiom achieves.President-elect, Dr. Jason Babby, introduced Dr. Jamie Chin, a PGY-1 resident from Winthrop University Hospital, for the evening’s clinical pearl presentation. She discussed the treatment and management of Febrile neutropenia. Febrile neutropenia is an medical emergency and complication of chemotherapy. It is seen most commonly when patients present during their nadir, which occurs 7-14 days after treatment. The Multinational Association of Supportive Care in Cancer (MASCC) risk index score is a widely used tool to assess the patients risk level to help determine empiric antibiotic therapy. Patients will require treatment with an empiric anti-pseudomonal agent within two hours of diagnosis. Subsequently the spectrum of activity may be narrowed upon cultures and sensitivities.
President-elect Babby, introduced Dr. Aniwaa Owusu-Obeng, a Clinical Pharmacogenomics Coordinator from The Mount Sinai Hospital. Dr. Owusu-Obeng introduced how legislation and the human genome project prompted the boom of pharmacogenetics. Since then, there have been grants from the government funding research and development in special institutions to continue building a human data bank to study the patients genetic material and medication response to differences in genetics.
Dr. Owusu-Obeng explained how phase I and phase II drug metabolism varies among individuals and is studied in pharmacogenomic analysis. Such reactions include oxidation, hyrolysis, conjugation, and glucuronidation, which may be altered in rate or extent. She discussed cases that prompted pharmacogenomics reserach and began with examples with codeine and mothers and infants, but that soon lead to discovering effects with many more therapeutic treatments.Some therapeutic areas where pharmacogenomics has been quite useful are in oncology, cardiovascular, psychiatric disorders, and diabetes. Nonetheless, there has been utility seen is many areas of pharmacotherapeutics.The evening concluded with a lovely dinner and networking among members.Photos by Gretchen Marcelino, Peter Hoang, and Sharmin Amjad
Article by Jamie Chin